(PRVA) Privia Health - Overview

Sector: Healthcare | Industry: Health Information Services | Exchange: NASDAQ (USA) | Market Cap: 2.623m USD | Total Return: 4.2% in 12m

Physician Services, Technology, Management, Network
Total Rating 35
Safety 59
Buy Signal 0.40
Health Information Services
Industry Rotation: -3.9
Market Cap: 2.62B
Avg Turnover: 16.6M USD
ATR: 3.91%
Peers RS (IBD): 43.5
Risk 5d forecast
Volatility32.1%
Rel. Tail Risk-5.63%
Reward TTM
Sharpe Ratio0.09
Alpha-19.28
Character TTM
Beta0.784
Beta Downside1.322
Drawdowns 3y
Max DD46.24%
CAGR/Max DD-0.16
EPS (Earnings per Share) EPS (Earnings per Share) of PRVA over the last years for every Quarter: "2021-03": 0.06, "2021-06": -1.68, "2021-09": -0.09, "2021-12": -0.11, "2022-03": -0.16, "2022-06": 0.14, "2022-09": 0.01, "2022-12": 0.14, "2023-03": 0.06, "2023-06": 0.06, "2023-09": 0.05, "2023-12": 0.02, "2024-03": 0.02, "2024-06": 0.03, "2024-09": 0.03, "2024-12": 0.21, "2025-03": 0.22, "2025-06": 0.02, "2025-09": 0.29, "2025-12": 0.25, "2026-03": 0,
EPS CAGR: -58.25%
EPS Trend: 30.6%
Last SUE: -0.56
Qual. Beats: 0
Revenue Revenue of PRVA over the last years for every Quarter: 2021-03: 213.607, 2021-06: 225.756, 2021-09: 251.524, 2021-12: 275.333, 2022-03: 313.801, 2022-06: 335.536, 2022-09: 342.899, 2022-12: 364.424, 2023-03: 386.276, 2023-06: 413.351, 2023-09: 417.282, 2023-12: 440.828, 2024-03: 415.243, 2024-06: 422.326, 2024-09: 437.921, 2024-12: 460.9, 2025-03: 480.097, 2025-06: 521.153, 2025-09: 580.419, 2025-12: 541.173, 2026-03: null,
Rev. CAGR: 15.64%
Rev. Trend: 96.7%
Last SUE: 0.06
Qual. Beats: 0

Warnings

P/E ratio 117.8

Tailwinds

No distinct edge detected

Description: PRVA Privia Health

Privia Health Group, Inc. (NASDAQ: PRVA) is a national physician-enablement platform that partners with independent practices, health plans and health systems. It delivers integrated technology, population-health tools and management-services to streamline clinical workflows, reduce administrative burden, and align financial incentives through a single-TIN medical group and accountable-care organization (ACO) model.

In its most recent quarter (Q4 2025), Privia reported $276 million in revenue, a 12% year-over-year increase driven by higher ACO enrollment (+9%) and expanding payer contracts. Adjusted EBITDA margin improved to 8.4%, reflecting operational efficiencies from its technology stack. The broader health-care services sector is being propelled by accelerated adoption of value-based care contracts-U.S. Medicare Advantage enrollment grew 4.2% YoY in Q4 2025-and rising physician burnout, which fuels demand for outsourced management solutions like Privia’s.

For a deeper dive into how Privia fits into the evolving value-based care landscape, you might explore ValueRay’s analyst notes.

Headlines to Watch Out For
  • Value-based care model adoption drives revenue growth
  • Physician network expansion increases patient reach
  • Administrative service demand impacts operational costs
  • Regulatory changes in healthcare policy pose risk
Piotroski VR‑10 (Strict) 6.0
Net Income: 22.9m TTM > 0 and > 6% of Revenue
FCF/TA: 0.12 > 0.02 and ΔFCF/TA 2.66 > 1.0
NWC/Revenue: 16.13% < 20% (prev 22.21%; Δ -6.08% < -1%)
CFO/TA 0.12 > 3% & CFO 163.4m > Net Income 22.9m
Net Debt (-470.2m) to EBITDA (48.8m): -9.63 < 3
Current Ratio: 1.60 > 1.5 & < 3
Outstanding Shares: last quarter (130.4m) vs 12m ago 3.12% < -2%
Gross Margin: 9.61% > 18% (prev 0.10%; Δ 951.2% > 0.5%)
Asset Turnover: 169.5% > 50% (prev 152.9%; Δ 16.60% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' 1.20
A: 0.25 (Total Current Assets 911.0m - Total Current Liabilities 568.5m) / Total Assets 1.37b
B: -0.11 (Retained Earnings -156.3m / Total Assets 1.37b)
C: 0.03 (EBIT TTM 38.9m / Avg Total Assets 1.25b)
D: -0.27 (Book Value of Equity -155.1m / Total Liabilities 578.4m)
Altman-Z'' Score: 1.20 = BB
Beneish M -2.73
DSRI: 1.04 (Receivables 400.9m/316.2m, Revenue 2.12b/1.74b)
GMI: 1.06 (GM 9.61% / 10.19%)
AQI: 1.26 (AQ_t 0.33 / AQ_t-1 0.26)
SGI: 1.22 (Revenue 2.12b / 1.74b)
TATA: -0.10 (NI 22.9m - CFO 163.4m) / TA 1.37b)
Beneish M-Score: -2.73 (Cap -4..+1) = A
What is the price of PRVA shares? As of April 08, 2026, the stock is trading at USD 22.38 with a total of 756,847 shares traded.
Over the past week, the price has changed by +8.80%, over one month by -3.95%, over three months by -7.52% and over the past year by +4.19%.
Is PRVA a buy, sell or hold? Privia Health has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy PRVA.
  • StrongBuy: 14
  • Buy: 5
  • Hold: 2
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the PRVA price?
Analysts Target Price 32 42.8%
Privia Health (PRVA) - Fundamental Data Overview as of 05 April 2026
P/E Trailing = 117.8333
P/E Forward = 18.9753
P/S = 1.2358
P/B = 3.5351
Revenue TTM = 2.12b USD
EBIT TTM = 38.9m USD
EBITDA TTM = 48.8m USD
Long Term Debt = 9.53m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.20m USD (from shortTermDebt, last quarter)
Debt = 9.53m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -470.2m USD (from netDebt column, last quarter)
Enterprise Value = 2.15b USD (2.62b + Debt 9.53m - CCE 479.7m)
 Interest Coverage Ratio = unknown (Ebit TTM 38.9m / Interest Expense TTM 0.0)
 EV/FCF = 13.28x (Enterprise Value 2.15b / FCF TTM 162.2m)
FCF Yield = 7.53% (FCF TTM 162.2m / Enterprise Value 2.15b)
FCF Margin = 7.64% (FCF TTM 162.2m / Revenue TTM 2.12b)
Net Margin = 1.08% (Net Income TTM 22.9m / Revenue TTM 2.12b)
Gross Margin = 9.61% ((Revenue TTM 2.12b - Cost of Revenue TTM 1.92b) / Revenue TTM)
Gross Margin QoQ = 9.18% (prev 10.51%)
Tobins Q-Ratio = 1.57 (Enterprise Value 2.15b / Total Assets 1.37b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 9.53m)
Taxrate = 20.84% (2.79m / 13.4m)
NOPAT = 30.8m (EBIT 38.9m * (1 - 20.84%))
Current Ratio = 1.60 (Total Current Assets 911.0m / Total Current Liabilities 568.5m)
Debt / Equity = 0.01 (Debt 9.53m / totalStockholderEquity, last quarter 737.2m)
Debt / EBITDA = -9.63 (Net Debt -470.2m / EBITDA 48.8m)
Debt / FCF = -2.90 (Net Debt -470.2m / FCF TTM 162.2m)
Total Stockholder Equity = 697.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.83% (Net Income 22.9m / Total Assets 1.37b)
RoE = 3.29% (Net Income TTM 22.9m / Total Stockholder Equity 697.2m)
RoCE = 5.51% (EBIT 38.9m / Capital Employed (Equity 697.2m + L.T.Debt 9.53m))
RoIC = 4.42% (NOPAT 30.8m / Invested Capital 697.2m)
WACC = 8.71% (E(2.62b)/V(2.63b) * Re(8.74%) + D(9.53m)/V(2.63b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 8.74% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.59%
[DCF] Terminal Value 79.31% ; FCFF base≈139.0m ; Y1≈171.5m ; Y5≈292.6m
[DCF] Fair Price = 39.26 (EV 4.39b - Net Debt -470.2m = Equity 4.86b / Shares 123.7m; r=8.71% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 30.58 | EPS CAGR: -58.25% | SUE: -0.56 | # QB: 0
Revenue Correlation: 96.70 | Revenue CAGR: 15.64% | SUE: 0.06 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.27 | Chg7d=+0.000 | Chg30d=+0.003 | Revisions Net=+2 | Analysts=11
EPS current Year (2026-12-31): EPS=1.07 | Chg7d=+0.000 | Chg30d=+0.009 | Revisions Net=+5 | Growth EPS=+8.5% | Growth Revenue=+12.1%
EPS next Year (2027-12-31): EPS=1.20 | Chg7d=+0.000 | Chg30d=+0.015 | Revisions Net=-1 | Growth EPS=+11.8% | Growth Revenue=+10.4%
[Analyst] Revisions Ratio: +0.50 (3 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 7.9% (Discount Rate 8.7% - Earnings Yield 0.8%)
[Growth] Growth Spread = +5.1% (Analyst 13.0% - Implied 7.9%)
External Resources
Dataroma Stockcircle